Lupin Launches Formoflo-G® MDI, World's First Triple Combo Drug for COPD in India
Lupin Limited launched Formoflo-G® MDI, the world's first fixed-dose triple combination inhaler for COPD in India. The drug combines Glycopyrronium Bromide, Formoterol Fumarate, and Fluticasone Propionate. This launch aims to improve treatment outcomes for over 55 million COPD patients in India.
The product launch addresses a significant unmet medical need in a large patient population, positioning Lupin as a leader in the respiratory therapy segment.
The launch of a new, innovative drug that is the world's first in its category for managing COPD is a positive development for the company and patients.
Lupin Limited has launched Formoflo-G® MDI, the world's first fixed-dose triple combination metered-dose inhaler (MDI) for chronic obstructive pulmonary disease (COPD) in India. This launch follows approval from the Drug Controller General of India (DCGI) and marks a significant advancement in respiratory care.
Formoflo-G® MDI combines Glycopyrronium Bromide, Formoterol Fumarate, and Fluticasone Propionate for the long-term management of moderate to severe COPD. It is a twice-daily, single-strength fixed-dose product, offering a new treatment option for the over 55 million people in India living with COPD.
Nilesh Gupta, Managing Director, Lupin, stated that the launch reflects the company's commitment to addressing unmet patient needs through differentiated, high-quality therapies and aims to improve outcomes for patients with respiratory diseases. Rajeev Sibal, President – India Region Formulations, Lupin, added that Formoflo-G® MDI strengthens Lupin's respiratory portfolio and provides healthcare professionals with an important treatment option.
Ranked #2 in the respiratory therapy segment in India (IQVIA, MAT Mar 2026), Lupin continues to reinforce its leadership in respiratory care with this innovative product.
What to do with a filing like this
Lupin Limited filed this with the NSE as a statutory disclosure, categorised under product launches. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Lupin Limited. Read the original for the full detail.